The Most Important Facts About Smith & Nephew

By Emilio Sanchez • Friday, June 30 09:49 • Permanent Link

Large-cap Health Care company Smith & Nephew has moved 1.9% so far today on a volume of 27,065, compared to its average of 896,401. In contrast, the S&P 500 index moved 1.0%.

Smith & Nephew trades -11.42% away from its average analyst target price of $36.17 per share. The 3 analysts following the stock have set target prices ranging from $32.0 to $39.5, and on average have given Smith & Nephew a rating of buy.

Anyone interested in buying SNN should be aware of the facts below:

Smith & Nephew's current price is 330.1% above its Graham number of $7.45, which implies that at its current valuation it does not offer a margin of safety
Smith & Nephew has moved 1237.0% over the last year, and the S&P 500 logged a change of 1493.0%
Based on its trailing earnings per share of 0.51, Smith & Nephew has a trailing 12 month Price to Earnings (P/E) ratio of 62.8 while the S&P 500 average is 15.97
SNN has a forward P/E ratio of 17.0 based on its forward 12 month price to earnings (EPS) of $1.89 per share
Its Price to Book (P/B) ratio is 13.25 compared to its sector average of 4.16
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Based in Watford, the company has 19,012 full time employees and a market cap of $13.99 Billion. Smith & Nephew currently returns an annual dividend yield of 1.2%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.